New York State Common Retirement Fund Raises Stock Position in Smith & Nephew SNATS, Inc. (NYSE:SNN)

New York State Common Retirement Fund raised its stake in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) by 19.5% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 291,148 shares of the medical equipment provider's stock after acquiring an additional 47,567 shares during the period. New York State Common Retirement Fund owned approximately 0.07% of Smith & Nephew SNATS worth $8,260,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in SNN. J. Goldman & Co LP purchased a new position in shares of Smith & Nephew SNATS in the fourth quarter valued at approximately $47,700,000. Causeway Capital Management LLC purchased a new position in shares of Smith & Nephew SNATS in the fourth quarter valued at approximately $11,820,000. Northern Trust Corp boosted its stake in shares of Smith & Nephew SNATS by 169.9% in the fourth quarter. Northern Trust Corp now owns 508,392 shares of the medical equipment provider's stock valued at $12,496,000 after purchasing an additional 320,054 shares during the period. Point72 Asset Management L.P. purchased a new position in shares of Smith & Nephew SNATS in the fourth quarter valued at approximately $6,132,000. Finally, Raymond James Financial Inc. purchased a new position in shares of Smith & Nephew SNATS in the fourth quarter valued at approximately $4,992,000. 25.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently commented on SNN shares. HSBC lowered shares of Smith & Nephew SNATS from a "buy" rating to a "hold" rating in a research note on Friday, April 25th. Hsbc Global Res downgraded shares of Smith & Nephew SNATS from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Finally, Canaccord Genuity Group lifted their price target on shares of Smith & Nephew SNATS from $27.00 to $28.00 and gave the stock a "hold" rating in a research note on Thursday, May 1st. Six research analysts have rated the stock with a hold rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $28.00.

Smith & Nephew SNATS Stock Up 2.9%

Shares of NYSE:SNN traded up $0.90 during trading on Wednesday, hitting $31.83. 760,878 shares of the company were exchanged, compared to its average volume of 821,647. The stock has a market capitalization of $13.94 billion, a P/E ratio of 14.74, a PEG ratio of 0.95 and a beta of 0.69. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.89 and a quick ratio of 1.33. Smith & Nephew SNATS, Inc. has a 12-month low of $23.69 and a 12-month high of $31.84. The firm's 50 day moving average price is $29.64 and its 200-day moving average price is $27.77.

About Smith & Nephew SNATS

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.